[Determination of epidermal growth factor receptor expression in malignant ovarian tumors using radioligand assay].
The objective of the authors was to determine in a prospective study EGFR level of expression in ovarian cancer. For a period of 2 years EGFR expression was studied in 23 patients having malignant ovarian tumors by 125I-labelled human epidermal growth factor and recombinant human epidermal growth factor. EGFR expression was observed in 56.5% of the cases. Insignificant mucinous and clear cell cancers prevailed in the EGFR/+/ group. All patients having wider metastasis were EGFR/+/, as this dependency was statistically significant (p = 0.017). Radioligand binding assays enabled exact quantitative determination of EGFR expression in malignant ovarian tumors. Statistically significant relation existed between the ovarian cancer metastatic potential and EGFR expression level.
Tomov
S
S
Tsingilev
D
D
Gorchev
G
G
Velkova
A
A
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis / Q000096:biosynthesis*; D001706:Biopsy; D066246:ErbB Receptors / Q000032:analysis / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology; D011869:Radioligand Assay
D014408:Biomarkers, Tumor; D066246:ErbB Receptors